Indovis

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indovis

What is Indovis? Defining Its Identity and Purpose

Property Description
Active ingredient Indometacin (Indomethacin)
Form Capsules, tablets, suppositories, solutions for injection
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Provides anti-inflammatory, analgesic, and antipyretic effects
Origin Synthetic compound (Indole derivative)

Indovis is a prescription-only medicinal product identified by its active substance, Indometacin (or Indomethacin). It belongs to the powerful Nonsteroidal Anti-inflammatory Drug (NSAID) pharmacological class. This substance is a synthetic compound, chemically classified as an indole derivative, which is clinically recognized for its potent ability to inhibit prostaglandin synthesis. This positions Indovis as a medication typically reserved for adults requiring substantial systemic action against severe pain and inflammation, distinguishing it from less potent, over-the-counter NSAID options.

Composition and Available Pharmaceutical Preparations

The medicine's formulation is a single-component product (monotherapy), ensuring its therapeutic action is focused solely through the established mechanism of Indometacin. Indometacin preparations are readily available in various dosage forms, including capsules and tablets for oral intake, rectal suppositories, and sterile solutions for injection (parenteral route). This availability across multiple pharmaceutical preparations is a key feature, allowing medical professionals to select the optimal route for systemic delivery.

General Therapeutic Purpose and Core Action

The general therapeutic purpose of Indovis centers on providing powerful systemic relief by modulating key physiological responses associated with discomfort. Its action is designed to deliver a potent anti-inflammatory effect and significant analgesic effect (pain relief), alongside a reliable antipyretic effect (fever reduction). Indometacin is characterized as a compound of high efficacy within the NSAID group. This confirms its role as a strong option where the general reduction of swelling, pain, and fever is medically required.

Regulatory References

  1. Indomethacin - NIH StatPearls

What side effects are possible with Indovis?

Possible Side Effects and Safety Information for Indovis

Serious Adverse Reactions (Boxed Warnings)

Official regulatory documents emphasize two major, life-threatening risks associated with this class of medication:

  • Cardiovascular Thrombotic Events: The drug may increase the risk of serious, potentially fatal, cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. This risk may increase with the duration of use.
  • Gastrointestinal Events: An increased risk of serious, sometimes fatal, gastrointestinal bleeding, ulceration, and perforation of the stomach or intestines exists. Elderly patients are at a greater risk for these events.

Common and Less Common Adverse Reactions

The most common adverse reactions reported in clinical trials, occurring in 3% or more of patients, include headache, dizziness, dyspepsia (indigestion), and nausea.

Less common adverse reactions involve acid or sour stomach, diarrhea, vomiting, stomach discomfort, and skin rash.

Clinically Significant Safety Concerns

Other serious adverse reactions documented in regulatory labeling include:

  • Hepatotoxicity (liver injury) and elevated liver enzymes.
  • Renal Toxicity (kidney damage), potentially leading to acute renal failure.
  • Hypersensitivity Reactions, including severe anaphylactic reactions and serious, rare skin reactions (e.g., Stevens-Johnson Syndrome).
  • Hypertension (high blood pressure) and heart failure.

Safety Restrictions and Population Considerations

  • Contraindications: The drug is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and in patients with a history of aspirin-sensitive asthma or other allergic reactions to NSAIDs.
  • Pregnancy: Use of the drug must be avoided starting at 30 weeks of pregnancy due to the risk of premature closure of the fetal ductus arteriosus.

The lowest effective dosage should be used for the shortest possible duration to minimize the potential for serious adverse events.

Overdose and Emergency Response

The Indovis (Indometacin) overdose profile is based strictly on descriptions found in official government regulatory documents.

Documented Overdose Presentations

Clinical manifestations of an overdose primarily affect the Central Nervous System (CNS) and Gastrointestinal (GI) systems. CNS effects may include severe headache, dizziness, confusion, agitation, and unusual drowsiness. GI manifestations often involve nausea, vomiting (which may include blood), and epigastric pain. Systemic signs, such as fluctuations in blood pressure and increased heart rate, are also documented.

Severe Systemic Outcomes

Overdose carries the potential for severe systemic escalation, which regulatory sources confirm can lead to life-threatening complications. These serious outcomes include seizures, coma, acute renal failure, liver damage, and significant internal bleeding. Regulatory information notes that elderly patients are at an increased risk of serious adverse outcomes.

Immediate Actions and Management

Upon the finding or suspicion of an overdose, official guidance mandates the immediate seeking of medical help right away. This requires contacting local emergency services or a Poison Control Center.

Management is symptomatic and supportive, as no specific antidote is known. Procedures described in official documents may include the consideration of activated charcoal or gastric lavage under specified conditions, along with continuous monitoring of vital signs and laboratory tests.

Therapeutic Uses of Indovis

What Indovis Treats: Main Uses and Benefits

Indovis (Indometacin) is applied across therapeutic domains involving heightened inflammation and pain, playing a role in managing symptoms when symptoms are challenging or interfere with functional stability. The medication is relevant for conditions marked by increased systemic or localized discomfort.

The primary therapeutic use of Indovis is to provide relief for conditions characterized by periods of heightened symptoms, including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute gouty arthritis, and short-term inflammatory conditions like bursitis and tendinitis. The medication is applied in addressing symptom clusters that may become intense or disruptive, such as moderate to severe pain, joint swelling, and associated fever.

“Indovis is commonly used when short-term symptomatic assistance is needed, offering supportive relief during acute episodes and chronic symptom flares.”

It is applied during phases of increased distress or discomfort where symptoms create noticeable functional strain. By offering symptomatic relief, Indovis contributes to improved day-to-day comfort and supports general well-being during symptomatic phases. It may assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Use in Managing Joint Inflammation and Stiffness The medication is relevant for easing symptoms related to inflammatory or irritative states and may assist with managing both the pain and swelling that limit joint movement.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Indovis (Indometacin) is restricted to specific patient groups, as defined by governmental regulatory authorities. Use is generally established for adults but is governed by several critical constraints and absolute prohibitions.

Absolute Prohibitions

The medicine is strictly contraindicated for patients who have experienced hypersensitivity or allergic reactions (like asthma or urticaria) after taking aspirin or any other Nonsteroidal Anti-inflammatory Drug (NSAID). Use is also prohibited in the setting of coronary artery bypass graft (CABG) surgery and for individuals with active peptic ulceration or a history of recurrent gastrointestinal bleeding. Absolute non-eligibility applies to patients with severe heart failure, advanced renal disease, or severe hepatic failure.

Age and Physiological Restrictions

Regulatory documents state that the safety and efficacy of oral and rectal formulations are not established for children younger than 14 years of age. Older adults are advised to use the drug with greater caution due to increased susceptibility to adverse effects. For pregnancy, use is restricted after 20 weeks gestation and is formally contraindicated starting at 30 weeks gestation and later. Use during breastfeeding is generally not recommended.

What should I know about interactions with other medicines?

Indovis Interactions with other medicines and products

Indovis (Indometacin) has officially documented interaction patterns that are detailed in regulatory prescribing information. These interactions involve effects on drug concentration and additive pharmacodynamic risks.

Formally Contraindicated and Restricted Combinations

Classification Interacting Substance Description (Official Restriction)
Contraindicated Diflunisal Co-administration is prohibited; this combination increases Indometacin plasma levels and decreases its renal clearance, presenting a significant risk of gastrointestinal hemorrhage.
Restricted Other NSAIDs Co-administration with other NSAIDs, including COX-2 selective inhibitors, is not generally recommended due to an increased risk of gastrointestinal toxicity.

Pharmacodynamic and Exposure Interactions

Indovis may reduce the desired effects of several classes of medicines. Concomitant use with Antihypertensive Agents (e.g., ACE inhibitors, ARBs) and Diuretics may diminish their effectiveness in lowering blood pressure or promoting fluid loss.

Indovis can also increase the exposure of certain co-administered drugs. It has been reported to increase the serum concentration and prolong the half-life of Lithium and Digoxin. It may also potentiate the toxicity of Methotrexate by decreasing its tubular secretion. Co-administration with Anticoagulants or other drugs that interfere with hemostasis significantly increases the risk of bleeding.


Non-Medicinal Product Interactions

Regulatory information notes that the risk of gastrointestinal ulcers or bleeding is increased with co-administration of Alcohol or a history of Smoking.

Mechanism of Action

The drug Indovis (Indomethacin) is a nonsteroidal agent that exerts its effects by engaging several key mechanistic domains, primarily through the modulation of eicosanoid synthesis.

Cyclooxygenase (COX) Enzyme Inhibition

Indovis functions as a non-selective, reversible inhibitor of both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This action modifies early molecular steps by suppressing the conversion of arachidonic acid into prostaglandins. The resulting decrease in prostaglandin concentration alters cellular signaling pathways and reduces the output of key inflammatory mediators.

Modulation of Inflammatory Mediators

Beyond COX inhibition, the compound restricts the migration and accumulation of leukocytes to specific sites and stabilizes lysosomal membranes. This modifies downstream signaling sequences to reduce the release of lysosomal enzymes, leading to altered physiological responses within affected tissues.

Influence on Central Signaling

Indovis modulates specific mediators within the central nervous system. It has been shown to reduce cerebral blood flow through the modulation of nitric oxide pathways and the induction of intracranial vasoconstriction. This pathway adjustment results in consequences that include the modulation of vascular tone.

Dosage and Administration Information

The administration of Indovis (Indometacin) is based on the principle of using the lowest effective dosage for the shortest duration necessary. The medicine is available for oral, rectal, or intravenous (IV) routes of administration.

Oral forms, including capsules and suspension, must be taken with food, immediately after meals, or with antacids to ensure proper intake conditions. Extended-release capsules are subject to the special procedural condition that they must be swallowed whole and cannot be opened, crushed, or chewed. If a scheduled dose is missed, the patient must not double the dose to make up for the missed amount.

For chronic conditions such as rheumatoid arthritis, the starting oral dose is typically 25 mg two or three times daily. This dosage may be gradually increased by 25 mg or 50 mg at weekly intervals until the maximum daily limit of 200 mg for immediate-release forms is reached. For acute gouty arthritis, the dose is 50 mg three times a day, which is then rapidly reduced to cessation once symptoms are tolerable. Treatment for acute painful shoulder is typically limited to a course of 7 to 14 days.

Specific population instructions require that the drug be used with greater care in older adults. The IV injectable form is reserved for specific pediatric use and must be reconstituted with preservative-free diluents, then administered as an infusion over 20 to 30 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Indovis

This section provides an overview of the official research evidence for Indovis (Indometacin), focusing on the types of studies conducted and what outcomes they were designed to measure, according to authoritative governmental and scientific sources. The evidence base is predominantly composed of Randomized Controlled Trials (RCTs) and supporting observational data.


Evidence Base for Chronic Inflammatory Arthritis Conditions

This section summarizes the evidence structure for Indovis in managing moderate to severe Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), detailing the types of randomized controlled trials and observational studies that regulators have referenced in the context of symptomatic outcomes.

Research Profile in Rheumatoid Arthritis (RA)

Indovis was studied for use in adults with Rheumatoid Arthritis (RA), a condition characterized by fluctuating or episodic manifestations. Research primarily involved short-term RCTs that looked at how symptoms change over time, and observational settings evaluating daily-life functioning.

Studies were conducted during periods of increased symptom activity and monitored patient-reported outcomes describing perceived discomfort. Researchers examined changes in pain scores, objective outcomes related to joint swelling and tenderness, and the duration of morning stiffness. Functional outcomes reflecting daily functioning or activity level were also monitored. Studies report the patterns of change observed in the populations related to these symptomatic axes, providing context on how symptoms evolved.

Research Profile in Ankylosing Spondylitis (AS)

The role of Indovis in Ankylosing Spondylitis (AS) was evaluated in studies focusing on this condition associated with acute or disruptive episodes. Studies monitored outcomes related to systemic or functional imbalance. Trial reports describe the patterns of symptomatic change observed in the studied populations, which were aligned with the general profile of the pharmacological class. The research focused on symptomatic outcomes only; the evidence base does not assess the agent's impact on underlying disease changes.


Evidence Base for Osteoarthritis and Acute Inflammatory Pain

The evidence for Osteoarthritis (OA) comes mainly from Randomized Controlled Trials exploring how symptoms change over time. These studies examined outcomes such as pain intensity, joint stiffness, and daily functioning or activity level. Data show patterns related to symptom changes during the study period, generally aligning with the known pharmacological profile of this class of agents when used for conditions involving periods of heightened symptoms.

Evidence for Acute Gouty Arthritis Flares

Indovis was studied for use in acute gouty arthritis, a condition associated with acute or disruptive episodes. The research examined outcomes describing episodic or acute changes, primarily focusing on the timing and magnitude of the observed symptomatic shifts and the time needed for joint tenderness and swelling to subside. Research highlights changes measured during the study period, demonstrating data that show patterns related to the rapid evolution of symptoms following intervention.


Research Gaps and Areas of Scientific Uncertainty

Long-term effects are not fully established by prospective RCTs, and there is limited information available for outcomes monitored over extended periods. The available research is focused on symptomatic findings; there are no data to suggest that the medicine alters the underlying pathogenesis or progressive course of chronic diseases like RA or AS. Furthermore, comparative evidence is lacking in some areas to provide a high degree of certainty regarding its symptomatic patterns when compared to all other available treatment options. It is important to remember that study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Indovis (FAQ)


Q: What is the main thing Indovis is prescribed for?

According to official product labeling, Indovis (Indometacin) is indicated for managing several inflammatory conditions. These approved uses include moderate to severe rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is also prescribed for acute conditions such as gouty arthritis flares and acute painful shoulder.


Q: How quickly does Indovis usually start to work?

Official pharmacokinetic data describes the systemic absorption of the drug. The active ingredient, Indometacin, is generally well-absorbed, reaching its peak concentration in the blood approximately two hours after an oral dose. In studies of drug kinetics, nearly all of the dose was absorbed within four hours of intake.


Q: How long does the effect of Indovis typically last?

Official pharmacokinetic data indicates that the average half-life is approximately 4.5 hours. This figure reflects the time it takes for the body to eliminate half of the medication. Extended-release dosage forms are designed to maintain therapeutic blood concentrations for up to 12 hours.


Q: Does Indovis affect sleep patterns?

Official regulatory information indicates that Indovis may affect sleep patterns. Insomnia, which is difficulty sleeping, is listed as an uncommon adverse reaction. Additionally, Central Nervous System effects such as drowsiness and somnolence (sleepiness) have also been reported.


Q: Can Indovis cause problems with memory?

Memory loss is not directly listed as a side effect in regulatory documents. However, the official labeling does describe other Central Nervous System adverse reactions, including mental confusion, a feeling of 'muzziness,' and depersonalization, all of which may affect mental clarity and focus.


Q: Are there any specific foods or drinks to avoid while taking Indovis?

Official guidelines for oral forms state that the medication should be taken with food, immediately after meals, or with antacids. Furthermore, regulatory information advises against co-administration with alcohol, as this combination may significantly increase the risk of serious gastrointestinal bleeding.


Q: Is Indovis safe to use if I have high blood pressure?

According to official warnings, Indovis has the potential to cause new hypertension or worsen pre-existing high blood pressure. Regulatory documents state that Indovis is generally associated with a caution for use in patients with hypertension. Blood pressure should be monitored closely during the course of treatment.


Q: What is the risk of dependence or addiction with Indovis?

Indovis belongs to the pharmacological class known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and is not classified as a controlled substance. Because Indovis belongs to the NSAID class, official sources do not indicate a risk of physical or mental dependence or addiction.


Q: Can Indovis affect the results of blood tests?

Official warnings indicate that Indovis can influence the results of certain laboratory tests. These include the potential for abnormal liver function tests and elevated blood urea nitrogen (BUN) or creatinine, which are markers for kidney function. Monitoring of hemoglobin and hematocrit is also noted due to the risk of bleeding.


Q: Is Indovis commonly used by older adults?

Regulatory guidelines advise greater caution when Indovis is used in older adults. This is because official documents show this population has an increased susceptibility to serious adverse effects, particularly those involving the stomach and intestines. The principle of using the lowest effective dose for the shortest duration is especially important for this population, as noted in official guidelines.


Q: Is it normal to feel a bit nauseous when first starting Indovis?

Official clinical trial data reports nausea as one of the most common adverse reactions, meaning it was experienced by 3% or more of patients studied. While the regulatory label does not specifically address if nausea is transient or limited to the start of treatment, its prevalence suggests it is a known occurrence for many users.


Q: Can Indovis make you feel tired or dizzy during the day?

Official regulatory information lists dizziness as a common side effect. Additionally, other Central Nervous System adverse reactions such as extreme tiredness, fatigue, and drowsiness (somnolence) have been reported in the product information.


Q: What is the purpose of the different strengths of Indovis?

Different strengths of Indovis are manufactured to allow for flexible administration, which allows for flexibility based on the variety of conditions the drug may be prescribed for. For instance, the labeling notes that certain acute flares require higher initial doses than the lower maintenance doses used for chronic conditions.


Q: How long does Indovis stay in your system after stopping it?

Official pharmacokinetic data indicates that Indovis has a mean half-life of approximately 4.5 hours. This figure is a measure of the time needed for the body to reduce the amount of drug in the blood by half.


Q: What does 'contraindicated' mean regarding Indovis?

According to official prescribing information, a contraindication is a specific condition or circumstance where a drug must not be used because it could be potentially harmful. For Indovis, these are absolute prohibitions, such as a history of severe allergic reactions to NSAIDs or use in patients with severe heart failure.


Q: What kind of research has been done on the safety of Indovis?

The safety profile of Indovis is established through formal clinical trials and continuous post-marketing surveillance. This research established several serious risks, including cardiovascular thrombotic events (such as heart attack or stroke), gastrointestinal bleeding, and potential toxicity to the liver and kidneys, all of which are documented in regulatory warnings.


Q: Can Indovis cause weight changes?

Weight gain and fluid retention, known as edema, are listed in official documents as less common metabolic adverse reactions associated with Indovis use. The labeling notes that unexplained weight gain or swelling should be brought to the attention of a healthcare provider.


Q: Does Indovis have any known drug-disease interactions with diabetes?

While not a formal drug-disease interaction, the official adverse reaction list includes hyperglycemia (high blood sugar) and glycosuria (glucose in the urine). These less common metabolic reactions may be relevant information for individuals managing blood sugar levels.


Q: Can Indovis cause changes in mood or personality?

Official regulatory information indicates that Indovis can cause Central Nervous System adverse reactions related to mood and personality. These reported effects include depression, listlessness, anxiety, nervousness, and, less commonly, psychic disturbances or psychotic episodes.


Q: What is the definition of a 'serious' side effect for Indovis?

A serious side effect, as described in regulatory warnings, is an outcome that is potentially life-threatening or requires emergency medical intervention. The most serious risks are detailed in the Boxed Warnings and include events such as heart attack, stroke, and major gastrointestinal bleeding or perforation.


Q: Are there any required warnings for people who drive or operate machinery while taking Indovis?

Yes, official patient information includes warnings regarding activities requiring mental alertness. Because Indovis has the potential to cause effects such as dizziness, drowsiness, and lightheadedness, regulatory patient information includes warnings against driving a car or operating machinery until the patient knows how the medication may affect them.


Q: What kind of monitoring might be needed while taking Indovis?

Regulatory guidance recommends that blood pressure should be monitored when initiating therapy and throughout the course of treatment. Additionally, due to the potential risks to the liver and kidneys, monitoring of liver and renal function may be necessary, especially for patients at high risk.


Q: Is Indovis suitable for long-term use?

Official regulatory principles emphasize using the lowest effective dose for the shortest possible duration. This guidance applies even when the drug is used for chronic conditions, due to the serious risks associated with cardiovascular events (like heart attack or stroke) and gastrointestinal bleeding.


Q: What should I know about taking Indovis with cold or flu medications?

The official interaction warnings are relevant when considering cold or flu medications. Co-administration with other NSAIDs (a common ingredient in many relief products) is generally not recommended. Additionally, Indovis may diminish the blood pressure-lowering effect of certain drugs, which can sometimes be found in cold remedies.

How should Indovis be stored and disposed of?

How to Store and Dispose of Indovis?

Indovis (Indomethacin) must be stored and handled according to specific guidelines set by regulatory authorities to ensure product stability and safety.

Storage Conditions

Requirement Description (Capsules and Suspension)
Temperature Store at Controlled Room Temperature between 20 C to 25 C (68 F to 77 F).
Excursions Permitted temperature excursions range from 15 C to 30 C (59 F to 86 F).
Safety The medication must be kept out of the reach of children.

Disposal and Special Handling

All unused medicine, expired product, and containers must be disposed of according to local regulatory requirements. For the injectable form, any reconstituted solution that is not used immediately must be discarded as it does not contain a preservative, ensuring stability protocols are strictly followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indovis found in:

A-Z Index: